Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Early Alzheimer's Disease
NCT05468073Phase 2Active, not recruiting
- Sponsor
- Centre Hospitalier Sainte-Anne
- Start
- Oct 2022
- Primary completion
- Jun 2028
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in Alzheimer's disease (AD), sponsored by Centre Hospitalier Sainte-Anne. Started Oct 2022; status: active, not recruiting.
02
Drugs
aldesleukin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05468073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468073.